CureVac CVAC Stock
CureVac Price Chart
CureVac CVAC Financial and Trading Overview
| CureVac stock price | 3.23 USD |
| Previous Close | 10.17 USD |
| Open | 10.11 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 9.87 - 10.26 USD |
| 52 Week Range | 5.63 - 15.62 USD |
| Volume | 250.32K USD |
| Avg. Volume | 497.11K USD |
| Market Cap | 2.23B USD |
| Beta (5Y Monthly) | 2.869236 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0.82 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.98 USD |
CVAC Valuation Measures
| Enterprise Value | 1.7B USD |
| Trailing P/E | N/A |
| Forward P/E | -13.253333 |
| PEG Ratio (5 yr expected) | -1.11 |
| Price/Sales (ttm) | 44.34568 |
| Price/Book (mrq) | 3.1189206 |
| Enterprise Value/Revenue | 33.878 |
| Enterprise Value/EBITDA | -7.509 |
Trading Information
CureVac Stock Price History
| Beta (5Y Monthly) | 2.869236 |
| 52-Week Change | -30.34% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.62 USD |
| 52 Week Low | 5.63 USD |
| 50-Day Moving Average | 8.57 USD |
| 200-Day Moving Average | 8.28 USD |
CVAC Share Statistics
| Avg. Volume (3 month) | 497.11K USD |
| Avg. Daily Volume (10-Days) | 406.02K USD |
| Shares Outstanding | 223.85M |
| Float | 122.9M |
| Short Ratio | 6.51 |
| % Held by Insiders | 45.44% |
| % Held by Institutions | 24.43% |
| Shares Short | 4.2M |
| Short % of Float | 10.58% |
| Short % of Shares Outstanding | 1.87% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -478.10% |
| Gross Margin | -183.74% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -14.99% |
| Return on Equity (ttm) | -41.97% |
Income Statement
| Revenue (ttm) | 50.18M USD |
| Revenue Per Share (ttm) | 0.26 USD |
| Quarterly Revenue Growth (yoy) | -70.79% |
| Gross Profit (ttm) | -91549000 USD |
| EBITDA | -226372992 USD |
| Net Income Avi to Common (ttm) | -291355008 USD |
| Diluted EPS (ttm) | -1.71 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 617.52M USD |
| Total Cash Per Share (mrq) | 2.76 USD |
| Total Debt (mrq) | 41.15M USD |
| Total Debt/Equity (mrq) | 5.77 USD |
| Current Ratio (mrq) | 7.607 |
| Book Value Per Share (mrq) | 3.187 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -249252000 USD |
| Levered Free Cash Flow (ttm) | -298620256 USD |
Profile of CureVac
| Country | United States |
| State | N/A |
| City | Tübingen |
| Address | Friedrich-Miescher-Strasse 15 |
| ZIP | 72076 |
| Phone | 49 7071 9883 0 |
| Website | https://www.curevac.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 904 |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Q&A For CureVac Stock
What is a current CVAC stock price?
CureVac CVAC stock price today per share is 3.23 USD.
How to purchase CureVac stock?
You can buy CVAC shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CureVac?
The stock symbol or ticker of CureVac is CVAC.
Which industry does the CureVac company belong to?
The CureVac industry is Biotechnology.
How many shares does CureVac have in circulation?
The max supply of CureVac shares is 227.25M.
What is CureVac Price to Earnings Ratio (PE Ratio)?
CureVac PE Ratio is 3.93902440 now.
What was CureVac earnings per share over the trailing 12 months (TTM)?
CureVac EPS is 0.82 USD over the trailing 12 months.
Which sector does the CureVac company belong to?
The CureVac sector is Healthcare.
CureVac CVAC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}